Targeted NLRP3 inhibition during the early to mid‐phases of sepsis progression may help restore immune equilibrium by reducing pro‐inflammatory cytokine release while avoiding suppression of anti‐inflammatory mediators. Here, NLRP3 is linked to Sepsis.